FDA Approves Newly Revised Prescribing Information For AZILECT(R) Reducing Medication And Food Restrictions

Teva Pharmaceutical Industries, Ltd. (NASDAQ: TEVA) announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions. This update was based on clinical data that confirmed the mechanism of action of AZILECT® as a selective MAO-B (monoamine oxidase-B) inhibitor at the recommended doses of 1 mg and 0.5 mg…

Here is the original: 
FDA Approves Newly Revised Prescribing Information For AZILECT(R) Reducing Medication And Food Restrictions

Related posts:

1. FDA Approves ZEGERID OTC(TM) For Over-the-Counter Treatment Of Frequent Heartburn Merck & Co., Inc. announced that the U.S. Food and Drug Administration (FDA) has approved ZEGERID OTC(TM) (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules), for over-the-counter treatment of frequent heartburn....
2. FDA Approves Intravenous Formulation Of Pfizer’s Revatio(R) (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in...
3. Thyroid Journal Publishes Newly Revised Guidelines For Managing Thyroid Cancer The American Thyroid Association has released new, revised Management Guidelines for the diagnosis and treatment of patients with thyroid nodules and thyroid cancer. The new guidelines are published in Thyroid,...
4. FDA Approves Lilly’s Zyprexa For Two Adolescent Indications The U.S. Food and Drug Administration (FDA) approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I...
5. FDA Approves New Drug For Rare Cancer Cutaneous T-Cell Lymphoma The US Food and Drug Administration (FDA) has approved a new drug for treating patients with the rare white blood cell cancer Cutaneous T-cell Lymphoma (CTCL); the drug Istodax (romidepsin)...
6. FDA Approves New Drug For Pain That Persists After Shingles The US Food and Drug Administration (FDA) announced yesterday that it has approved Qutenza (capsaicin) 8% patch for the treatment of post-herpetic neuralgia (PHN), an often excruciating pain that can...
7. FDA Approves Generic Aricept To Treat Dementia Related To Alzheimer’s Disease Please note this is a corrected version of a press release that was posted to FDA's website today. The corrections include a modified headline and a revised second paragraph. The...
8. FDA Approves Gloucester Pharmaceuticals’ ISTODAX(R) For Patients With Cutaneous T-cell Lymphoma Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least...
9. FDA Unveils Safe Use Initiative That Targets Preventable Harm From Medication Use The U.S. Food and Drug Administration announced the Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use. "Too many people suffer unnecessary injuries...
10. FDA Approves Agriflu Seasonal Influenza Vaccine The U.S. Food and Drug Administration approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B. ...
11. FDA Approves Kalbitor For Treating Potentially Life-Threatening Attacks Of Hereditary Angioedema The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition...
12. FDA Approves Lysteda To Treat Heavy Menstrual Bleeding The U.S. Food and Drug Administration approved Lysteda tablets (tranexamic acid), the first non-hormonal product cleared to treat heavy menstrual bleeding (menorrhagia). Lysteda works by stabilizing a protein that helps...
13. US FDA Approves SEROQUEL XR(R) For Add-On Treatment Of Major Depressive Disorder AstraZeneca (NYSE: AZN) announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults...
14. FDA Approves Gloucester Pharmaceuticals’ ISTODAX(R) For Patients With Cutaneous T-cell Lymphoma Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least...
15. FDA Approves First Additive Solution For Platelet Storage Up To 5 Days The U.S. Food and Drug Administration approved InterSol, the first solution approved to replace a portion of plasma used when storing platelets for up to five days, allowing some of...

« ProImmune Launches Novel Class-Leading CFSE T Cell Proliferation Assays For Assessing Drug Immunogenicity Risk Fact About The Best Way to Do Sit Ups »